Scarica l'app Stockscreener
6.77
0.73%
-0.05
Dopo l'orario di chiusura:
6.88
0.11
+1.62%
Precedente Chiudi:
$6.82
Aprire:
$7.06
Volume 24 ore:
336.84K
Relative Volume:
1.75
Capitalizzazione di mercato:
$84.12M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-1.0945
EPS:
-6.1852
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
+18.98%
1M Prestazione:
+14.75%
6M Prestazione:
-64.87%
1 anno Prestazione:
-69.52%
Intervallo 1D:
$6.605
$7.19
Intervallo di 1 settimana:
$5.35
$7.19
Portata 52W:
$3.1301
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Confronta JSPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
6.77 | 84.12M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
When the Price of (JSPR) Talks, People Listen - news.stocktradersdaily.com
Draig Therapeutics launches with $140 million - The Pharma Letter
Solu Therapeutics appoints new COO - The Pharma Letter
Jasper Therapeutics Reports Positive Phase 1b/2a Study Results - TipRanks
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU market drives stock outlook - Investing.com Nigeria
Jasper releases new data on briquilimab from SPOTLIGHT trial - The Pharma Letter
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | - GuruFocus
JSPR: Promising Results from Phase 1b/2a Study of Briquilimab | JSPR Stock News - GuruFocus
Jasper Therapeutics Reports Positive Data from 180mg Cohort - GlobeNewswire
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential in CSU stock scrutinized - Investing.com Canada
Cantor Fitzgerald Weighs in on JSPR FY2026 Earnings - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
Wellington Management Group LLP Boosts Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Trend Tracker for (JSPR) - news.stocktradersdaily.com
Is Monster Beverage Stock Outperforming the S&P 500? - The Globe and Mail
Jane Street Group LLC Sells 2,502 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Warren Buffett Is Ready to Invest $100 Billion in a Stock That Meets These 3 Criteria - The Globe and Mail
Jasper Therapeutics Announces Acceptance of Four Abstracts for Presentation at EAACI Congress 2025 - Nasdaq
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Breakthrough Clinical Data: Jasper's Briquilimab Shows Promise in Treating Resistant Urticaria Cases - Stock Titan
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - Yahoo Finance
Buy Rating for Jasper Therapeutics: Potential Breakthrough with Briquilimab in CSU Market - TipRanks
Bank of America Corp DE Cuts Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Northern Trust Corp Trims Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
Market Analysis: May 26th, 2025 - The Globe and Mail
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment - Investing.com Canada
Jasper Therapeutics’ SWOT analysis: briquilimab stock potential in urticaria treatment By Investing.com - Investing.com South Africa
Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential - Insider Monkey
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stake Lifted by Deutsche Bank AG - Defense World
Spotify Stock's Rally Still Has Legs To Run Higher - The Globe and Mail
Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR - Defense World
Oppenheimer Cuts Jasper Therapeutics (NASDAQ:JSPR) Price Target to $65.00 - Defense World
Jasper Therapeutics (JSPR) Price Target Lowered by Oppenheimer | JSPR Stock News - GuruFocus
(JSPR) Trading Report - news.stocktradersdaily.com
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
William Blair Issues Pessimistic Outlook for JSPR Earnings - Defense World
Q2 EPS Forecast for Jasper Therapeutics Increased by Analyst - Defense World
Oppenheimer Cuts Price Target on Jasper Therapeutics to $65 From $80, Keeps Outperform Rating - marketscreener.com
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) - GuruFocus
Oppenheimer Adjusts Price Target for Jasper Therapeutics (JSPR) | JSPR Stock News - GuruFocus
Jasper Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Jasper Therapeutics to Present at RBC and Jefferies Global Healthcare Conferences on Briquilimab Development - Nasdaq
Jasper Therapeutics Showcases Novel Antibody Therapy at Major Healthcare Conferences This Summer - Stock Titan
UBS Maintains Buy Rating for Jasper Therapeutics (JSPR) Despite Price Target Adjustment | JSPR Stock News - GuruFocus
JSPR Price Target Adjusted by UBS Amidst Upcoming Clinical Updates | JSPR Stock News - GuruFocus
Jasper (JSPR) Advances Briquilimab with Promising Trial Results - GuruFocus
UBS Adjusts Price Target on Jasper Therapeutics to $33 From $38, Maintains Buy Rating - marketscreener.com
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs - TipRanks
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jasper Therapeutics Inc Azioni (JSPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mahal Jeetinder Singh | Chief Operating Officer |
Dec 12 '24 |
Sale |
22.11 |
900 |
19,899 |
25,009 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):